Leading the way in landmark prostate cancer study

Two men standing in a room with medical equipment
Fiona Stanley Hospital Head of Urology Professor Dickon Hayne and GenesisCare Radiation Oncologist Dr Tee Lim.
August 2, 2018

Fiona Stanley Hospital (FSH) has become the highest recruiting site in Australia and the second highest recruiting site in the world for a landmark prostate cancer clinical trial.

The ENZARAD study is looking at a new generation hormone drug being used in combination with radiotherapy.

Local lead investigator, GenesisCare Radiation Oncologist, Dr Tee Lim has been supported by FSH Head of Urology Professor Dickon Hayne.

Dr Lim hopes this second generation drug will improve the gold standard of treatment for patients with high risk prostate cancer.

“Patients take the medication for two years and are followed up for 10 years so we can assess cancer recurrence and survival rates,” Dr Lim said.

“Presently, nearly 40 per cent of these patients with serious prostate cancer die within 10 years and we are hoping to reduce this figure.”

FSH has recruited 60 patients to this study and been acknowledged for their high recruitment levels.

Professor Dickon Hayne believes FSH has been successful with recruitment because of the robust practice for patient diagnosis and treatment.

“All patients who go through the FSH prostate cancer clinic are discussed at a multidisciplinary meeting covering diagnosis and treatment options,” Professor Hayne said.

“These comprehensive meetings provide a collaborative approach and opportunity to discuss relevant trials that could be suitable for patients.”

The study is also underway in the United Kingdom, Ireland, New Zealand and United States of America and has been sponsored by Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and TROG Cancer Research.

Read more about our research in the South Metropolitan Health Service Research Report 2017 (PDF 3.4MB).